NCT05907486View on ClinicalTrials.gov

The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2025

Conditions
Thrombotic Disorder
Interventions
DRUG

N-acetyl-cysteine

8g/d (\>=45kg); 200mg/kg.d (\<45kg), intravenously for at least 4 hours, day -9 to day +45

DRUG

Busulfan

3.2mg/kg, day-7 to day -5, intravenously

DRUG

Cytarabine

2g/m2, day -8, intravenously

DRUG

Cyclophosphamide

1.8g/m2, day -4 to day -3, intravenously

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER